Soichiro Takai

Summary

Affiliation: Kansai Medical University
Country: Japan

Publications

  1. ncbi Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer
    Soichiro Takai
    Department of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan
    Pancreas 36:e26-32. 2008
  2. ncbi Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer
    Sohei Satoi
    Department of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan
    Pancreas 38:282-8. 2009
  3. ncbi Postoperative outcomes in patients with hepatocellular carcinomas resected with exposure of the tumor surface: clinical role of the no-margin resection
    Yoichi Matsui
    Department of Surgery, Kansai Medical University, 2 3 1 Shinmachi, Hirakata, Osaka 573 1191, Japan
    Arch Surg 142:596-602; discussion 603. 2007
  4. ncbi Pre-operative patient selection of pancreatic cancer patients by multi-detector row CT
    Sohei Satoi
    Department of Surgery and of Radiology, Kansai Medical University, Osaka, Japan
    Hepatogastroenterology 56:529-34. 2009
  5. ncbi Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial
    Naoyoshi Terakawa
    Department of Surgery, Kansai Medical University, Osaka, Japan
    Nutr Cancer 60:643-51. 2008
  6. ncbi Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer
    Kanji Takahashi
    Department of Surgery, Kansai Medical University, 10-15, Fumizono, Moriguchi, 570-8507, Japan
    Cancer Immunol Immunother 55:775-84. 2006
  7. ncbi Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer
    Naoyoshi Terakawa
    Departments of Surgery, Kansai Medical University, Osaka, Japan
    Pancreas 33:31-7. 2006
  8. ncbi Circulating dendritic cells and development of septic complications after pancreatectomy for pancreatic cancer
    Kanji Takahashi
    Department of Surgery, Kansai Medical University, 2 3 1, Shin Machi, Hirakata, Osaka, 573 1191, Japan
    Arch Surg 142:1151-7; discussion 1157. 2007
  9. ncbi A new guideline to reduce postoperative morbidity after pancreaticoduodenectomy
    Sohei Satoi
    Department of Surgery, Kansai Medical University, Osaka, Japan
    Pancreas 37:128-33. 2008
  10. ncbi Clinical impact of multidetector row computed tomography on patients with pancreatic cancer
    Sohei Satoi
    Department of Surgery, Kansai Medical University, 2 3 1 Shin machi, Hirakata, Osaka 573 1191, Japan
    Pancreas 34:175-9. 2007

Collaborators

Detail Information

Publications18

  1. ncbi Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer
    Soichiro Takai
    Department of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan
    Pancreas 36:e26-32. 2008
    ....
  2. ncbi Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer
    Sohei Satoi
    Department of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan
    Pancreas 38:282-8. 2009
    ..The results of surgical therapy alone for pancreatic cancer are disappointing. We explored surgical results after neoadjuvant chemoradiation therapy (NACRT) for patients with pancreatic cancer that extended beyond the pancreas...
  3. ncbi Postoperative outcomes in patients with hepatocellular carcinomas resected with exposure of the tumor surface: clinical role of the no-margin resection
    Yoichi Matsui
    Department of Surgery, Kansai Medical University, 2 3 1 Shinmachi, Hirakata, Osaka 573 1191, Japan
    Arch Surg 142:596-602; discussion 603. 2007
    ..We hypothesized that no-margin resections for hepatocellular carcinoma do not negatively affect patient outcomes...
  4. ncbi Pre-operative patient selection of pancreatic cancer patients by multi-detector row CT
    Sohei Satoi
    Department of Surgery and of Radiology, Kansai Medical University, Osaka, Japan
    Hepatogastroenterology 56:529-34. 2009
    ....
  5. ncbi Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial
    Naoyoshi Terakawa
    Department of Surgery, Kansai Medical University, Osaka, Japan
    Nutr Cancer 60:643-51. 2008
    ..No significant differences in PHA, NK cell activity, and cytokine production were found between groups. AHCC intake resulted in the increased number of DCs and function of DC1s, which have a role in specific immunity...
  6. ncbi Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer
    Kanji Takahashi
    Department of Surgery, Kansai Medical University, 10-15, Fumizono, Moriguchi, 570-8507, Japan
    Cancer Immunol Immunother 55:775-84. 2006
    ..When a patient remained disease free, the recovery of cDC1 counts was observed approximately 12 months after pancreatectomy. Further strategy will be needed to improve immune function in patients with pancreatic cancer...
  7. ncbi Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer
    Naoyoshi Terakawa
    Departments of Surgery, Kansai Medical University, Osaka, Japan
    Pancreas 33:31-7. 2006
    ..A method of assessing the capability of leukocytes, particularly macrophages, to produce TNF-alpha could be useful for prognostis and for monitoring immunocompetence in patients with pancreatic cancer who have undergone chemotherapy...
  8. ncbi Circulating dendritic cells and development of septic complications after pancreatectomy for pancreatic cancer
    Kanji Takahashi
    Department of Surgery, Kansai Medical University, 2 3 1, Shin Machi, Hirakata, Osaka, 573 1191, Japan
    Arch Surg 142:1151-7; discussion 1157. 2007
    ..To investigate whether circulating dendritic cells in patients with pancreatic cancer is a risk factor for septic complications after pancreatectomy...
  9. ncbi A new guideline to reduce postoperative morbidity after pancreaticoduodenectomy
    Sohei Satoi
    Department of Surgery, Kansai Medical University, Osaka, Japan
    Pancreas 37:128-33. 2008
    ..Pancreaticoduodenectomy (PD) is still associated with high morbidity. To reduce the frequency of postoperative complications, we have made revisions in perioperative managements of pancreaticoduodenectomy...
  10. ncbi Clinical impact of multidetector row computed tomography on patients with pancreatic cancer
    Sohei Satoi
    Department of Surgery, Kansai Medical University, 2 3 1 Shin machi, Hirakata, Osaka 573 1191, Japan
    Pancreas 34:175-9. 2007
    ....
  11. ncbi Less morbidity after pancreaticoduodenectomy of patients with pancreatic cancer
    Sohei Satoi
    Department of Surgery, Kansai Medical University, Osaka, Japan
    Pancreas 33:45-52. 2006
    ..One result of this additional surgical stress may be that postoperative complications in patients with pancreatic cancer are more frequent than in patients with periampullary cancer...
  12. ncbi Clinical outcome of 214 liver resections using microwave tissue coagulation
    Sohei Satoi
    Department of Surgery, Kansai Medical University, Osaka, Japan
    Hepatogastroenterology 52:1180-5. 2005
    ..Herein, we report the clinical outcome of 214 patients with HCC who underwent non-anatomical liver resection using MTC in accordance with the tumor size...
  13. ncbi Impaired function of circulating dendritic cells in patients with pancreatic cancer
    Hiroaki Yanagimoto
    Department of Surgery, Kansai Medical University, Osaka, Japan
    Clin Immunol 114:52-60. 2005
    ..DCs were tested for the ability to stimulate allogeneic T lymphocytes in mixed leukocyte reaction (MLR). CD4/8, NK activity, PHA, and TGF-beta1 were also measured...
  14. ncbi Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer
    Hiroaki Yanagimoto
    Department of Surgery, Kansai Medical University, 2 3 1 Shinmachi, Hirakata, Osaka 573 1191, Japan
    Cancer Sci 98:605-11. 2007
    ..GEM did not inhibit the immune responses induced by personalized peptide vaccinations, and this new type of immunochemotherapy combination is recommended for further clinical study in APC patients...
  15. ncbi Inflammatory pseudotumors of the pancreas and liver with infiltration of IgG4-positive plasma cells
    Kazushige Uchida
    Third Department of Internal Medicine, Kansai Medical University, Moriguchi
    Intern Med 46:1409-12. 2007
    ..Histopathologic findings showed fibrosis and infiltration of IgG4-positive plasmacytes, suggesting IPT. The present case suggests a possible common mechanism in the development of AIP and IPT of the liver...
  16. ncbi Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study
    Yoichi Matsui
    First Department of Surgery, Kansai Medical University, 10 15 Fumizono, Moriguchi, Osaka 570 8507, Japan
    J Hepatol 37:78-86. 2002
    ..However, the effects of AHCC in a clinical setting have not been reported. We seek to determine whether AHCC can improve the prognosis of hepatocellular carcinoma (HCC) patients following surgical treatment...
  17. ncbi Intrahepatic sarcomatoid cholangiocarcinoma
    Masaki Kaibori
    First Department of Surgery, Kansai Medical University, 10-15 Fumizonocho, Moriguchi 570-8507, Japan
    J Gastroenterol 38:1097-101. 2003
    ..The patient had an uneventful postoperative course. However, she died 3 months after surgery from dissemination of the carcinoma. The literature on this rare disease is reviewed and discussed...
  18. ncbi Enhancement of circulating dendritic cell activity by immunomodulators (OK432 and KP-40)
    Hideyoshi Toyokawa
    First Department of Surgery, Kansai Medical University, Moriguchi, Osaka, Japan
    Anticancer Res 22:2137-45. 2002
    ..Therefore, DCs pulsed with OK432 and KP-40 could be applied to vaccination as a new adjuvant for specific immunotherapies...